AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 272 min read$THC

Blunt Roy sold (to issuer) $86K of THC

Blunt Roy sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · Blunt Roy
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

Because the transaction is a small director sale and explicitly coded as a sale to the issuer, it is more consistent with routine liquidity/buyback participation than a fundamental change; traders may treat it as sentiment noise unless paired with other negative signals.

02

Market read

Monitor for patterns, but the disclosed transaction alone is unlikely to drive a sustained move in THC.

03

What to watch

The code indicates sale to the issuer (often buyback mechanics), and the filing provides no rationale or broader context for interpreting intent.

Relevance 6/10Timing: Immediate for monitoring (Form 4 filed 2026-05-26, transaction dated 2026-05-22), but not a catalyst.

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare, reported via EDGAR.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Blunt Roy sold 493 shares to the issuer at $173.78/share, reducing holdings to 5,189 shares (SEC Form 4).

Expected impact

Likely minimal price impact; any reaction should be muted unless accompanied by unusual volume or broader insider selling trends.

Evidence & confidence

This is a routine Form 4 insider transaction with no accompanying operational or financial catalyst described in the filing details provided.

Market effects

Sector

No sector read-across; this is company-specific insider transaction disclosure only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the sale is part of repeated insider selling, it could be a mild bearish signal despite the issuer-sale code.

Key entities

  • issuer
    Tenet Healthcare Corp

    Subject of the SEC Form 4 insider transaction; director sold 493 shares at $173.78/share.

  • director
    Blunt Roy

    Reported insider who sold shares to the issuer; holdings after transaction: 5,189 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

THC insider trading history →

Related articles

OCT 5
$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

simplywall.st2 min
SEP 30
$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

theglobeandmail.com2 min
SEP 26
$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

insidermonkey.com3 min
SEP 20
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

simplywall.st3 min
SEP 9
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

simplywall.st2 min